This is a repository copy of Geographic variation in the treatment of non ST-segment elevation myocardial infarction: a national cohort study.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/113306/

Version: Accepted Version

Proceedings Paper:

https://doi.org/10.1093/eurheartj/ehw434

© The Authors 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. This is a pre-copyedited, author-produced version of a conference abstract published in European Heart Journal following peer review. The version of record, Dondo, et al., European Society of Cardiology Congress 2016, Rome, Italy, 27 Aug 2016 - 31 Aug 2016. European Heart Journal. Oxford University Press. 37: 1177-1178. 01 Aug 2016; is available online at: https://doi.org/10.1093/eurheartj/ehw434.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Title: Geographic variation in the treatment of non ST-segment elevation myocardial infarction: a national cohort study.

Authors:

1 T.B. Dondo, 1 M. Hall, 2 A. D. Timmis, 10 A.T. Yan, 3 P.D. Batin, 4 G. Oliver, 1 O.A. Alabas, 5 P.D. Norman, 6 J.E. Deanfield, 7 K. Bloor, 8 H. Hemingway, 1,9 C.P. Gale.

Affiliations:

1 Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, LS2 9JT, UK.

2 The National Institute for Health Biomedical Research Unit, Barts Health, London, EC1A 7BE, UK.

3 Department of Cardiology, The Mid Yorkshire Hospitals NHS Trust, Wakefield, WF1 4DG, UK.

4 National Health Service cardiac service user, West Yorkshire, UK

5 School of Geography, University of Leeds, LS2 9JT, UK

6 National Institute for Cardiovascular Outcomes Research, University College London, London, W1T 7HA, UK.

7 Department of Health Sciences, University of York, York, YO10 5DD, UK

8 The Farr Institute, University College London, London, WC1E 6BT, UK.

9 York Teaching Hospital NHS Foundation Trust, York, YO31 8HE, UK.

10 Department of Medicine, University of Toronto, Toronto, Canada.

Background: Between country investigations suggest variation in guideline-indicated treatment and outcomes for non ST-segment elevation myocardial infarction (NSTEMI). Yet, little is known about within country variation in NSTEMI care.

Purpose: To investigate within country variation in provision of guideline-indicated treatments for NSTEMI.
**Methods:** National cohort study (232 hospitals, 357,228 NSTEMI in England, 2003-13) using data from the Myocardial Ischaemia National Audit Project (MINAP). We used a four level hierarchical Poisson model adjusted for patient baseline characteristics to quantify variation amongst Clinical Commissioning Group, CCG (n= 211 ) in the provision of ESC guideline-indicated treatments according to their date of publication.

**Results:** The proportion of NSTEMI who received all care opportunities for which they were eligible was low (13.5% (48,257)) and varied between CCGs (median 12.8%, IQR 0.7 to 18.1%) (Figure 1). The greatest variation was for provision of aldosterone antagonists (16.7%, 0.0 to 40.0%) and least for use of an ECG (96.7%, 92.5 to 98.7%). The highest rates of care were for acute aspirin (median 92.8%, IQR 88.6 to 97.1%), as well as aspirin (90.1%, 85.1 to 93.3%) and statins (86.4%, 82.3 to 91.2%) at hospital discharge. The lowest rates were for smoking cessation advice (median 11.6%, IQR 8.7 to 16.6%), dietary advice (32.4%, 23.9 to 41.7%) and the prescription of P2Y12 inhibitors (39.7%, 32.4 to 46.9%). After adjustment for case mix, nearly all (99.6%) of the remaining variation in provision of care was due to between hospitals differences (median 64.7%, IQR 57.4% to 70.0%; between hospital variance: 1.92, 95% confidence interval 1.51 to 2.44; ICC 0.996, 0.976 to 0.999).

**Conclusions:** Despite international recommendation for the management of NSTEMI, there is evidence for wide within country variation in the use of guideline-indicated treatments for NSTEMI. Improved adherence to guidelines will help reduce premature cardiovascular death across Europe.